Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1983 2
1986 2
1987 2
1988 2
1989 1
1991 2
1992 2
1993 2
1994 6
1995 2
1996 3
1997 1
1998 1
2000 1
2002 2
2003 2
2004 1
2005 1
2006 3
2007 5
2008 4
2009 7
2010 5
2011 8
2012 5
2013 8
2014 10
2015 12
2016 11
2017 14
2018 10
2019 10
2020 12
2021 21
2022 25
2023 23
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Tapinarof for the treatment of psoriasis.
Nogueira S, Rodrigues MA, Vender R, Torres T. Nogueira S, et al. Among authors: vender r. Dermatol Ther. 2022 Dec;35(12):e15931. doi: 10.1111/dth.15931. Epub 2022 Oct 21. Dermatol Ther. 2022. PMID: 36226669 Free PMC article. Review.
Leadership: an overview.
Vender RJ. Vender RJ. Am J Gastroenterol. 2015 Mar;110(3):362-7. doi: 10.1038/ajg.2014.199. Epub 2014 Jul 22. Am J Gastroenterol. 2015. PMID: 25047400 Review.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. Bissonnette R, et al. Among authors: vender r. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. N Engl J Med. 2024. PMID: 38324484 Clinical Trial.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Among authors: vender r. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
Molecular source attribution.
Chao E, Chato C, Vender R, Olabode AS, Ferreira RC, Poon AFY. Chao E, et al. Among authors: vender r. PLoS Comput Biol. 2022 Nov 17;18(11):e1010649. doi: 10.1371/journal.pcbi.1010649. eCollection 2022 Nov. PLoS Comput Biol. 2022. PMID: 36395093 Free PMC article. No abstract available.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB. Thaçi D, et al. Among authors: vender r. Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021. Br J Dermatol. 2023. PMID: 36689515 Clinical Trial.
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Rull EV, Llamas-Velasco M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Torres T, et al. Among authors: vender r. Am J Clin Dermatol. 2022 Nov;23(6):891-904. doi: 10.1007/s40257-022-00722-y. Epub 2022 Aug 17. Am J Clin Dermatol. 2022. PMID: 35976568
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirisap N, Haustrup N, Gallo G, Schuster C, Brunner PM. Piaserico S, et al. Among authors: vender rb. Front Med (Lausanne). 2023 Jun 29;10:1185523. doi: 10.3389/fmed.2023.1185523. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37457564 Free PMC article.
205 results